#	Pagina
attuale pagina	/open-h2020/projects/197009/index.html

Opendata, web and dolomites

RAIL SIGNED

Radiomics of lung cancer (RAIL): non-invasive stratification of tumour heterogeneity for personalised cancer therapy

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

RAIL project word cloud

Explore the words cloud of the RAIL project. It provides you a very rough idea of what is the project "RAIL" about.

pet 85 500 pttheragnostic primarily underlies deaths biomarkers actionable burden costly life billion 20 59 stratify radiomics nor lung optimal validate worldwide ultimately doctors performed reduce nsclc death published million reduces efficient places trials tumour communications imaging com staging look progression heterogeneity ct cancers qualify nature quality highest 1958 guide annually ready eur lack treatment personalise prognostic cancer 18 surgical stratification accurate patient prognosis inter perform cell site 30 founded healthcare strategies evaluation therapeutic mainly trial ineffective market operability clinical prediction economic biomarker animation rail tumours acquired routine disease tnm patients breakthrough small see

Project "RAIL" data sheet

The following table provides information about the project.

Coordinator	PT THERAGNOSTIC BV Organization address address: OXFORDLAAN 55 BIOPARTNER BUILDING city: MAASTRICHT postcode: 6229 EV website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.oncoradiomics.com
Total cost	2˙427˙593 €
EC max contribution	2˙427˙593 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-2-2014
Funding Scheme	SME-2
Starting year	2015
Duration (year-month-day)	from 2015-06-01 to 2020-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	PT THERAGNOSTIC BV PT THERAGNOSTIC BV Organization address address: OXFORDLAAN 55 BIOPARTNER BUILDING city: MAASTRICHT postcode: 6229 EV website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	coordinator	2˙427˙593.00

Map

Project objective

Lung cancer is the most common cause of death from cancer worldwide with 1.59 million deaths annually. It also places the highest economic burden of all cancers on the EU with EUR 18.8 billion. Non-small cell lung cancer (NSCLC) comprises 85% of all lung cancer cases. The current clinical routine to guide treatment for NSCLC patients is primarily based on the TNM staging system founded in 1958, mainly to look at surgical operability. However, TNM-based evaluation, nor doctors prediction do not provide an accurate prognosis. The heterogeneity between patients (inter-patient), tumours (inter-tumour) and even within one tumour (intra-tumour) underlies these highly variable prognosis and presents a major clinical challenge. There is a lack of easy to perform, ‘actionable’ biomarkers to stratify NSCLC patients which results in i) under-treatment in 20% of NSCLC patients leading to disease progression and ultimately death, ii) over-treatment in 30% of NSCLC patients which reduces the quality of life of patients and places an economic burden on the healthcare system and iii) ineffective clinical trial design, due to lack of optimal stratification, which requires very large, costly clinical trials to be performed in order to bring new therapeutic strategies to the market. ptTheragnostic has developed breakthrough technology, called “Radiomics”, which was recently published in Nature Communications, which enables patient stratification through the use of imaging biomarkers acquired from routine CT & PET imaging (see animation on www.pttheragnostic.com). In Radiomics for lung cancer (RAIL) we will validate and qualify a multi-site level I imaging biomarker together with a ready-to-use application to deliver more accurate prognostic information, personalise treatment for NSCLC patients, reduce healthcare costs by EUR 500 million and enable efficient clinical trial design.

Deliverables

List of deliverables.
CE approval	Demonstrators, pilots, prototypes	2019-07-22 16:50:22
Annual update communication and dissemination plan M48	Documents, reports	2019-07-22 16:50:20
Completion of patient accrual	Demonstrators, pilots, prototypes	2019-07-22 16:50:23
Annual update communication and dissemination plan M36	Documents, reports	2019-07-22 16:50:21
Medical ethical approval of the phase II protocol in all centres	Documents, reports	2019-07-22 16:50:21
Dissemination material and updates	Documents, reports	2019-05-30 12:53:05
Online version of public web site	Websites, patent fillings, videos etc.	2019-05-30 12:53:10
Detailed communication and dissemination plan	Documents, reports	2019-05-30 12:53:11
Annual update communication and dissemination plan	Documents, reports	2019-05-30 12:53:13
Research protocol written and distributed to all participating centres	Documents, reports	2019-05-20 13:05:27
Design History File	Documents, reports	2019-05-20 13:05:26
Exploitation plan and annual updates	Documents, reports	2019-05-20 13:05:27

Take a look to the deliverables list in detail: detailed list of RAIL deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2016	Weimiao Wu, Chintan Parmar, Patrick Grossmann, John Quackenbush, Philippe Lambin, Johan Bussink, Raymond Mak, Hugo J. W. L. Aerts Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2016.00071	Frontiers in Oncology 6	2019-07-08
2016	Sara Carvalho, Esther G.C. Troost, Judith Bons, Paul Menheere, Philippe Lambin, Cary Oberije Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer â€“ A survival model with external validation published pages: 487-494, ISSN: 0167-8140, DOI: 10.1016/j.radonc.2016.04.024	Radiotherapy and Oncology 119/3	2019-07-08
2015	Chintan Parmar, Patrick Grossmann, Derek Rietveld, Michelle M. Rietbergen, Philippe Lambin, Hugo J. W. L. Aerts Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2015.00272	Frontiers in Oncology 5	2019-07-08
2016	Philippe Lambin, Jaap Zindler, Ben G.L. Vanneste, Lien Van De Voorde, DaniÃ«lle Eekers, Inge Compter, Kranthi Marella Panth, Jurgen Peerlings, Ruben T.H.M. Larue, Timo M. Deist, Arthur Jochems, Tim Lustberg, Johan van Soest, Evelyn E.C. de Jong, Aniek J.G. Even, Bart Reymen, Nicolle Rekers, Marike van Gisbergen, Erik Roelofs, Sara Carvalho, Ralph T.H. Leijenaar, Catharina M.L. Zegers, Maria Jacobs Decision support systems for personalized and participative radiation oncology published pages: , ISSN: 0169-409X, DOI: 10.1016/j.addr.2016.01.006	Advanced Drug Delivery Reviews	2019-07-08
2015	Ralph T.H. Leijenaar, Georgi Nalbantov, Sara Carvalho, Wouter J.C. van Elmpt, Esther G.C. Troost, Ronald Boellaard, Hugo J.W.L Aerts, Robert J. Gillies, Philippe Lambin The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis published pages: 11075, ISSN: 2045-2322, DOI: 10.1038/srep11075	Scientific Reports 5	2019-07-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAIL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RAIL" are provided by the European Opendata Portal: CORDIS opendata.